FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038472314> ?p ?o ?g. }

• W2038472314 endingPage "1195" @default.
• W2038472314 startingPage "1187" @default.
• W2038472314 abstract "p38 MAPK inhibition has potential myocardial protective effects. We assessed losmapimod, a potent oral p38 MAPK inhibitor, in patients with non-ST-segment elevation myocardial infarction (NSTEMI) in a double-blind, randomised, placebo-controlled trial.From October, 2009, to November, 2011, NSTEMI patients were assigned oral losmapimod (7·5 mg or 15·0 mg loading dose followed by 7·5 mg twice daily) or matching placebo in a 3:3:2 ratio. Safety outcomes were serious adverse events and alanine aminotransferase (ALT) concentrations over 12 weeks, and cardiac events (death, myocardial infarction, recurrent ischaemia, stroke, and heart failure) at 90 days. Efficacy outcomes were high-sensitivity C-reactive protein (hsCRP) and B-type natriuretic peptide (BNP) concentrations at 72 h and 12 weeks, and troponin I area under the curve (AUC) over 72 h. The losmapimod groups were pooled for analysis. This trial is registered with ClinicalTrials.gov, number NCT00910962.Of 535 patients enrolled, 526 (98%) received at least one dose of study treatment (losmapimod n=388 and placebo n=138). Safety outcomes did not differ between groups. HsCRP concentrations at 72 h were lower in the losmapimod group than in the placebo group (geometric mean 64·1 nmol/L, 95% CI 53·0-77·6 vs 110·8 nmol/L, 83·1-147·7; p=0·0009) but were similar at 12 weeks. Early geometric mean BNP concentrations were similar at 72 h but significantly lower in the losmapimod group at 12 weeks (37·2 ng/L, 95% CI 32·3-42·9 vs 49·4 ng/L, 38·7-63·0; p=0·04). Mean troponin I AUC values did not differ.p38 MAPK inhibition with oral losmapimod was well tolerated in NSTEMI patients and might improve outcomes after acute coronary syndromes.GlaxoSmithKline." @default.
• W2038472314 created "2016-06-24" @default.
• W2038472314 creator A5010936003 @default.
• W2038472314 creator A5014449865 @default.
• W2038472314 creator A5014777482 @default.
• W2038472314 creator A5029129626 @default.
• W2038472314 creator A5029868235 @default.
• W2038472314 creator A5033070568 @default.
• W2038472314 creator A5038373261 @default.
• W2038472314 creator A5041446600 @default.
• W2038472314 creator A5043249527 @default.
• W2038472314 creator A5043658281 @default.
• W2038472314 creator A5049666846 @default.
• W2038472314 creator A5054452062 @default.
• W2038472314 creator A5054954452 @default.
• W2038472314 creator A5061549677 @default.
• W2038472314 creator A5070387023 @default.
• W2038472314 creator A5073109157 @default.
• W2038472314 creator A5079103734 @default.
• W2038472314 creator A5079698562 @default.
• W2038472314 date "2014-09-01" @default.
• W2038472314 modified "2023-10-16" @default.
• W2038472314 title "Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial" @default.
• W2038472314 cites W1539898358 @default.
• W2038472314 cites W1972407368 @default.
• W2038472314 cites W1985272590 @default.
• W2038472314 cites W2018352107 @default.
• W2038472314 cites W2026014239 @default.
• W2038472314 cites W2029014360 @default.
• W2038472314 cites W2032307233 @default.
• W2038472314 cites W2050334022 @default.
• W2038472314 cites W2057226991 @default.
• W2038472314 cites W2057284363 @default.
• W2038472314 cites W2065685023 @default.
• W2038472314 cites W2065907781 @default.
• W2038472314 cites W2067091172 @default.
• W2038472314 cites W2096379722 @default.
• W2038472314 cites W2115013301 @default.
• W2038472314 cites W2147389584 @default.
• W2038472314 cites W2167844644 @default.
• W2038472314 cites W3030817736 @default.
• W2038472314 doi "https://doi.org/10.1016/s0140-6736(14)60417-7" @default.
• W2038472314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24930728" @default.
• W2038472314 hasPublicationYear "2014" @default.
• W2038472314 type Work @default.
• W2038472314 sameAs 2038472314 @default.
• W2038472314 citedByCount "117" @default.
• W2038472314 countsByYear W20384723142014 @default.
• W2038472314 countsByYear W20384723142015 @default.
• W2038472314 countsByYear W20384723142016 @default.
• W2038472314 countsByYear W20384723142017 @default.
• W2038472314 countsByYear W20384723142018 @default.
• W2038472314 countsByYear W20384723142019 @default.
• W2038472314 countsByYear W20384723142020 @default.
• W2038472314 countsByYear W20384723142021 @default.
• W2038472314 countsByYear W20384723142022 @default.
• W2038472314 countsByYear W20384723142023 @default.
• W2038472314 crossrefType "journal-article" @default.
• W2038472314 hasAuthorship W2038472314A5010936003 @default.
• W2038472314 hasAuthorship W2038472314A5014449865 @default.
• W2038472314 hasAuthorship W2038472314A5014777482 @default.
• W2038472314 hasAuthorship W2038472314A5029129626 @default.
• W2038472314 hasAuthorship W2038472314A5029868235 @default.
• W2038472314 hasAuthorship W2038472314A5033070568 @default.
• W2038472314 hasAuthorship W2038472314A5038373261 @default.
• W2038472314 hasAuthorship W2038472314A5041446600 @default.
• W2038472314 hasAuthorship W2038472314A5043249527 @default.
• W2038472314 hasAuthorship W2038472314A5043658281 @default.
• W2038472314 hasAuthorship W2038472314A5049666846 @default.
• W2038472314 hasAuthorship W2038472314A5054452062 @default.
• W2038472314 hasAuthorship W2038472314A5054954452 @default.
• W2038472314 hasAuthorship W2038472314A5061549677 @default.
• W2038472314 hasAuthorship W2038472314A5070387023 @default.
• W2038472314 hasAuthorship W2038472314A5073109157 @default.
• W2038472314 hasAuthorship W2038472314A5079103734 @default.
• W2038472314 hasAuthorship W2038472314A5079698562 @default.
• W2038472314 hasConcept C126322002 @default.
• W2038472314 hasConcept C142724271 @default.
• W2038472314 hasConcept C164705383 @default.
• W2038472314 hasConcept C197934379 @default.
• W2038472314 hasConcept C204787440 @default.
• W2038472314 hasConcept C27081682 @default.
• W2038472314 hasConcept C2771771 @default.
• W2038472314 hasConcept C2775915353 @default.
• W2038472314 hasConcept C2778198053 @default.
• W2038472314 hasConcept C500558357 @default.
• W2038472314 hasConcept C71924100 @default.
• W2038472314 hasConcept C90924648 @default.
• W2038472314 hasConceptScore W2038472314C126322002 @default.
• W2038472314 hasConceptScore W2038472314C142724271 @default.
• W2038472314 hasConceptScore W2038472314C164705383 @default.
• W2038472314 hasConceptScore W2038472314C197934379 @default.
• W2038472314 hasConceptScore W2038472314C204787440 @default.
• W2038472314 hasConceptScore W2038472314C27081682 @default.
• W2038472314 hasConceptScore W2038472314C2771771 @default.
• W2038472314 hasConceptScore W2038472314C2775915353 @default.
• W2038472314 hasConceptScore W2038472314C2778198053 @default.
• W2038472314 hasConceptScore W2038472314C500558357 @default.

• next